<DOC>
	<DOCNO>NCT01530594</DOCNO>
	<brief_summary>This randomized phase III trial CC-5013 ( lenalidomide , NSC-703813 ) low dose dexamethasone ( LLD ) versus bortezomib ( PS-341 , NSC-681239 ) , lenalidomide low dose dexamethasone ( BLLD ) induction , patient previously untreated multiple myeloma without intent immediate autologous stem cell transplant .</brief_summary>
	<brief_title>Lenalidomide Low Dose Dexamethasone Versus Bortezomib , Lenalidomide Low Dose Dexamethasone Induction , Patients With Previously Untreated Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Patients must newly diagnose multiple myeloma 2 . Patients must receive prior chemotherapy disease . Patients must receive prior radiotherapy large area pelvis ( half pelvis ) . Prior steroid treatment allow provide treatment 2 week duration . Patients must receive prior treatment bortezomib lenalidomide . 3 . Patients must ≥ 18 year age time registration . 4 . Patients must Zubrod Performance Status ( PS ) 0 3 5 . Patients must adequate marrow function define herein : 6 . Platelet count ≥ 80 x 103/mcL , 7 . ANC ≥ 1 x 103/mcL , Hemoglobin ( include patient either transfuse treat EPO ) ≥ 9 g/dL . 8 . Institutions must submit local cytogenetics report FISH analysis report 9 . Patients pathologic fracture , pneumonia diagnosis symptomatic hyperviscosity . 10 . Patients must calculate measured creatinine clearance &gt; 30 cc/min . 11 . Patients must uncontrolled , active infection require intravenous antibiotic 12 . Patients must psychiatric illness 13 . Patients must Hepatitis B , Hepatitis C HIV positive 14 . Patients must history cerebral vascular accident persistent neurologic deficit . 15 . Patients must able take aspirin 325 mg daily 16 . Females childbearing potential ( FCBP ) must negative serum urine pregnancy test 17 . No prior malignancy allow except adequately treat basal cell ( squamous cell ) skin cancer , situ cervical cancer cancer patient diseasefree five year . 18 . Patients must offer participation GEP molecular study evaluation genetic polymorphism .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Untreated</keyword>
	<keyword>Without intent immediate autologous stem cell transplant</keyword>
</DOC>